Synairgen Share Discussion Threads

[bobaxe1] 30/3/2020 12:39

Wow sells at 55, she's moving now

[nobbygnome] 30/3/2020 12:16

Actually it is. There was a famous case a couple of years ago although I am afraid I can't remember the name of the company. The MMs went short of a massive % of the stock.

[bmnsa] 30/3/2020 12:16

Cup and handle formed and passed,looking very good :))

[toffeeman] 30/3/2020 12:12

On your analysis it is possible to trade more than the share capital - which it clearly is not!

(Glad for the debate)

[jev1] 30/3/2020 12:11

Toffee

I think he already understands that.

Volume divided by two, rough rule of thumb for Buys and for Sells.

The way you've worded it though is pants because you could argue that the same shares are bought and sold continuously, so there's only ever 20,000 !

[nobbygnome] 30/3/2020 12:08

N n n nooooo!!

This is a MM lead stock so buys and sells are not directly connected. We all know that MMs can go long or short if they so choose. So sorry I don't agree....

[toffeeman] 30/3/2020 12:03

Come on Nobby:

If I buy 20,000 shares from someone who sells 20,000 then the number of shares traded is 20,000 NOT 40,000.

[nobbygnome] 30/3/2020 11:50

I said traded not bought! That is a fact...

[toffeeman] 30/3/2020 11:48

Nnnnnn NO NO Nobby!

At BEST divide by 2!

[nobbygnome] 30/3/2020 11:47

Good volume you have to say. We must be above 50% of the shares traded since the trial RNS the Wednesday before last. Any placing indigestion should be removed very easily with such a large churn.

[talk2dubya] 30/3/2020 11:46

60 p today ?

[bmnsa] 30/3/2020 11:44

Times investors are only just getting up after turning off the Teasmade in the bedroom.

[bobaxe1] 30/3/2020 11:28

Buys flying in, this will have to move soon

[tidy 2] 30/3/2020 10:41

Sunday Times Article in full BUY SynairgenThe Times article today reposted for anyone yet to see.As the world's top scientists and drugs giants strive to develop vaccines and experimental drugs to fight Covid-19, a little-known British company is already racing to the front line.Synairgen, listed on the London Stock Exchange and worth just £50m, is starting a clinical trial in hospitals across the UK with a drug it hopes will prevent coronavirus sufferers from falling seriously ill.Synairgen's technology uses a naturally occurring protein known as interferon beta, which orchestrates the body's antiviral response. It is used as a treatment for multiple sclerosis.Synairgen's team of experts has turned it into a drug that can be delivered through an inhaler. By boosting the lung's defence mechanisms, it is hoped the drug - known as SNG001 - will prevent patients from developing severe lower respiratory tract illnesses caused by infections such as Covid-19. Phase II trials in patients with asthma have already shown that it enhances the lung's antiviral defences.Synairgen will now test the treatment on 100 patients with coronavirus. Half will be given its new drug, half will get a placebo. Results could arrive in as soon as eight weeks, which could pave the way for a fast-tracked pivotal study in a bigger group of patients and rapid approval.A treatment could finally bring success for Synairgen. Since listing in 2004, its shares had fallen more than 95% - hit by a lack of funding and an overhang from investors including fallen stockpicker Neil Woodford. While shares in most of Britain's biggest companies have taken a hammering since the outbreak began, Synairgen's have climbed more than 300%, closing on Friday at 46p and giving the company a value of £50.3m.The run gave Synairgen the confidence last week to announce a £14m share placing, which brought in new investors including Polar Capital, while hedge fund Lansdowne increased its holding.Directors also bought shares, which were issued at 35p each - a 32% discount to the closing price on the day before the placing was announced. The new money will provide enough cash to complete the trial and start manufacturing the drug, should it be approved.For patients with pre-existing health conditions such as asthma, who are more at risk of complications from Covid-19, Synairgen could be on to a key treatment. Clinical trials are notoriously high-risk, but existing data shows its drug is well tolerated. Synairgen should have a part to play in the fightback against the pandemic. Buy

[hazl] 30/3/2020 10:12

always worth a look at their site for interest and updates its got a lot on the variety of things they have been associated with as well.Though of course we know where their priority is at present!

[diversification] 30/3/2020 09:38

Thank you someuwin, another reason for investing today is that the coverage this little company will get over the coming several weeks has only just started.

[talk2dubya] 30/3/2020 09:36

Think it’s fair to say the placing shares have been shifted from willing sellers!

[nobbygnome] 30/3/2020 09:24

A long way to go yet but yes looking very promising this morning...

[toffeeman] 30/3/2020 09:21

53.25 - 54 a few secs ago

[au24] 30/3/2020 09:19

Easily ;o)

[tburns] 30/3/2020 09:17

This will be breaching 60p shortly me thinks

[mo2550] 30/3/2020 09:12

Brakes off 53 plus